Foucar E, Erickson D G, Tung K S
Department of Pathology, University of New Mexico, Albuquerque.
J Clin Lab Immunol. 1979 Apr;2(1):79-84.
A 61-year-old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus (LE) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy. He was treated sequentially with prednisone and azathioprine (2 weeks), decreasing doses of prednisone alone (21 months), and no immunosuppressive drugs (10 months). Coincidental with this treatment, the immunopathology of the glomerulonephritis improved dramatically, dramatically, renal function returned almost to normal, and both antinuclear antibody and LE cell preparation became negative. The course of this patient's renal disease contrasts sharply with diffuse proliferative glomerulonephritis of idiopathic systemic lupus, and suggests that this rare complication of procainamide therapy may have a favorable course.
一名61岁男性在接受普鲁卡因胺治疗26个月后出现临床狼疮综合征，抗核抗体阳性、狼疮细胞检查阳性以及弥漫性增殖性肾小球肾炎。他先后接受了泼尼松和硫唑嘌呤治疗（2周），随后单独使用逐渐减量的泼尼松（21个月），最后未使用免疫抑制药物（10个月）。在此治疗过程中，肾小球肾炎的免疫病理学显著改善，肾功能几乎恢复正常，抗核抗体和狼疮细胞检查均转为阴性。该患者的肾脏疾病病程与特发性系统性红斑狼疮的弥漫性增殖性肾小球肾炎形成鲜明对比，提示普鲁卡因胺治疗这一罕见并发症可能有良好的病程。
